Leaflet ERBITUX 2mg / ml solution for infusion
Indicated for: colorectal cancer; head and neck cancer
Route of administration: infusion
Substance: cetuximab (monoclonal antibody)
ATC: L01FE01 (Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Egfr (epidermal growth factor receptor) inhibitors)
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Cetuximab is a monoclonal antibody used in the treatment of certain types of cancer, such as metastatic colorectal cancer and head and neck cancer. It works by blocking the epidermal growth factor receptor (EGFR), thereby inhibiting the growth and division of cancer cells.
Cetuximab is administered intravenously and is used either alone or in combination with other therapies, such as chemotherapy or radiation therapy. It is particularly indicated in patients with tumors that do not have KRAS gene mutations, as its effectiveness depends on this genetic factor.
Side effects may include skin reactions (acne-like rash), fatigue, nausea, diarrhea, hypomagnesemia, or severe allergic reactions. It is contraindicated in patients with hypersensitivity to cetuximab or other murine-derived proteins.
General data about ERBITUX 2mg / ml
- Substance: cetuximab
- Date of latest medicines list: 01-04-2026
- Product code: W43295001
- Concentration: 2mg / ml
- Pharmaceutical form: solution for infusion
- Quantity: 1
- Product type: Original
- Prescription status: S - Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.
Concentrations available for cetuximab
- 2mg/ml
- 5mg/ml